Evidence map›Paper›PMID 24740154›Full record

ArticlePloS one2014

Genome-wide association scan for variants associated with early-onset prostate cancer.

Ethan M Lange, Anna M Johnson, Yunfei Wang, Kimberly A Zuhlke, Yurong Lu, Jessica V Ribado, Gregory R Keele, Jin Li, Qing Duan, Ge Li and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cancer Progress and Priorities: Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  9. Article
  10. Article
  11. Cross-Cancer Pleiotropic Associations with Lung Cancer Risk in African Americans.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Impact of FTO SNPsArchives in cancer research · 2017
    Article
  19. Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Ethan M LangeDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Anna M JohnsonDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
Yunfei WangDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Kimberly A ZuhlkeDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
Yurong LuDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Jessica V RibadoDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Gregory R KeeleDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Jin LiDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Qing DuanDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Ge LiCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina, United States of America.
Zhengrong GaoCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina, United States of America.
Yun LiDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Jianfeng XuCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina, United States of America.
William B IsaacsDepartment of Urology, Johns Hopkins University, Baltimore, Maryland, United States of America.
Siqun ZhengCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina, United States of America.
Kathleen A CooneyDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America.
University of North Carolina at Chapel Hill · USWake Forest University · USMichigan United · USJohns Hopkins University · USUniversity of Michigan–Ann Arbor · US

Funding

VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 1995 to 2013
$31.3M
Genome-wide scan for genetic variants associated with early-onset prostate cancerR01CA136621 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 2009 to 2012
$2.4M
NCI NIH HHS P50 CA069568NCI NIH HHS P50-CA69568NCI NIH HHS R01 CA136621NCI NIH HHS R01-CA136621PHS HHS R01-F023000
6 · The paper itself

Abstract

Prostate cancer is the most common non-skin cancer and the second leading cause of cancer related mortality for men in the United States. There is strong empirical and epidemiological evidence supporting a stronger role of genetics in early-onset prostate cancer. We performed a genome-wide association scan for early-onset prostate cancer. Novel aspects of this study include the focus on early-onset disease (defined as men with prostate cancer diagnosed before age 56 years) and use of publically available control genotype data from previous genome-wide association studies. We found genome-wide significant (p<5×10(-8)) evidence for variants at 8q24 and 11p15 and strong supportive evidence for a number of previously reported loci. We found little evidence for individual or systematic inflated association findings resulting from using public controls, demonstrating the utility of using public control data in large-scale genetic association studies of common variants. Taken together, these results demonstrate the importance of established common genetic variants for early-onset prostate cancer and the power of including early-onset prostate cancer cases in genetic association studies.

Indexed as

AdultGenetic Association StudiesGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideProstatic Neoplasms

Identifiers

PMID24740154
PMCPMC3989171
OpenAlexW1970074436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.